A Universal Host-Directed Antiviral Platform: Unifying the p53/p21/NRF2 Axis, miR-34a/145/24-3p Epigenetic Switch, and Autophagy-Independent p62 Pan-Viral Restriction

Viruses are masters of adaptation. They change their shape and their genetic code so quickly that medicines designed to stop them often become useless within months. A drug that blocks one version of a virus might fail against the next, and vaccines can lose their edge as the pathogen evolves. Because of this, scientists have begun looking for a different kind of defense. Instead of trying to hit the virus directly, they are turning their attention to the human body itself. The idea is to strengthen the cell's own natural security systems, making the internal environment so hostile to infection that the virus cannot survive, regardless of how much it changes. This approach relies on the body's existing machinery: the proteins that regulate cell growth, the factors that manage stress, and the tiny molecules that control how genes are turned on or off.

In a new study, researchers have proposed a unified strategy that activates these internal defenses to fight a wide range of viruses, from the flu and herpes to coronaviruses. The team, led by Dr. Boominathan Lakshmanane, describes a multi-layered system that works by resetting the cell's internal balance. The process begins when the cell's master regulators, proteins known as p53 and NRF2, are activated. These regulators act like a central command center. When they are switched on, they trigger a chain reaction that does two critical things at once. First, they send out a signal to clean up the cell's genetic instructions, removing the specific signals that viruses use to hijack the cell. Second, they produce a specific protein that acts as a direct barrier, stopping the virus from copying itself.

The problem the researchers address starts with how some viruses, particularly coronaviruses, take over a cell. They force the cell to produce high levels of a protein called c-Myc, which is normally involved in cell growth. This excess c-Myc then triggers the production of a long strand of genetic material called PVT1. This strand acts like a sponge, soaking up tiny regulatory molecules called microRNAs that the cell needs to stay healthy. Specifically, it traps a molecule called miR-24-3p. When this molecule is trapped, it cannot do its job of silencing other proteins that help viruses enter the cell, such as NRP1 and NRP2, or proteins that help the virus build its own membranes. Without miR-24-3p, the cell becomes an open door for the virus, and its natural antioxidant defenses are shut down.

The proposed solution flips this script. By activating the p53 and NRF2 regulators, the cell produces two different microRNAs, miR-34a and miR-145. These molecules target the c-Myc protein and break it down. With c-Myc gone, the production of the PVT1 sponge stops. The sponge collapses, and the trapped miR-24-3p is released back into the cell's fluid. Once free, this molecule goes to work silencing the very proteins the virus needs to infect the cell. It shuts down the entry doors, stops the virus from building its lipid membranes, and turns off the inflammatory signals that viruses often exploit. At the same time, the activation of p53 leads to the production of another protein, p21, which helps stabilize the NRF2 regulator. This allows the cell to produce high levels of a protein called p62.

The p62 protein is particularly interesting because it acts as a broad-spectrum shield. The researchers found that p62 can stop viruses from replicating without needing the cell's usual waste-disposal system, known as autophagy, to function. This is a crucial distinction because many viruses can disable autophagy to survive. In this new model, p62 works independently, blocking the replication of positive-sense RNA viruses like SARS-CoV-2, negative-sense RNA viruses like the flu, and even double-stranded DNA viruses like herpes and vaccinia. The study also suggests that natural compounds, such as Biochanin A, could help stimulate this entire pathway, boosting the cell's antioxidant levels and providing a metabolic boost that supports the defense.

To test if this complex network could actually work in a living system, the researchers ran detailed computer simulations. These simulations modeled the behavior of the system over a 48-hour period. The results showed that once the initial signal was given, the system moved quickly. The levels of the harmful c-Myc protein dropped sharply, and the PVT1 sponge collapsed almost completely. This led to a massive recovery of the free miR-24-3p molecules, which then silenced the target proteins by more than 95 percent. The simulations also showed a temporary but powerful surge in the p62 restriction protein, rising ten times above normal levels to halt viral replication. The author notes that these findings are based on mathematical modeling and suggest that this dual approach—cleaning up the genetic hijacking while simultaneously deploying a direct protein barrier—could offer a mutation-resistant defense against a wide variety of viral threats.

The study does not claim to have a cure ready for immediate use, but it outlines a coherent biological framework that connects several known cellular pathways into a single, robust defense strategy. By focusing on the host rather than the virus, the approach aims to create a barrier that the virus cannot easily evolve around. The simulations provide a proof of concept, showing that the timing and intensity of these cellular responses are theoretically sufficient to stop the viral cycle. If this platform can be validated in laboratory experiments and eventually in clinical trials, it could represent a significant shift in how humanity prepares for future pandemics, moving from a game of catch-up with viral mutations to a strategy of strengthening the body's own inherent resilience.